MX389449B - Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. - Google Patents

Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.

Info

Publication number
MX389449B
MX389449B MX2020004724A MX2020004724A MX389449B MX 389449 B MX389449 B MX 389449B MX 2020004724 A MX2020004724 A MX 2020004724A MX 2020004724 A MX2020004724 A MX 2020004724A MX 389449 B MX389449 B MX 389449B
Authority
MX
Mexico
Prior art keywords
prevention
compositions
treatment
methods
inh
Prior art date
Application number
MX2020004724A
Other languages
English (en)
Other versions
MX2020004724A (es
Inventor
Cynthia Gallagher
Mark Cornell Manning
Steven Ruddy
Original Assignee
Viropharma Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX389449(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viropharma Biologics Llc filed Critical Viropharma Biologics Llc
Publication of MX2020004724A publication Critical patent/MX2020004724A/es
Publication of MX389449B publication Critical patent/MX389449B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones para el tratamiento y/o prevención de trastornos asociados con la deficiencia del inhibidor de C1 esterasa.
MX2020004724A 2013-03-15 2014-03-17 Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. MX389449B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
PCT/US2014/030309 WO2014145519A2 (en) 2013-03-15 2014-03-17 C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency

Publications (2)

Publication Number Publication Date
MX2020004724A MX2020004724A (es) 2022-01-18
MX389449B true MX389449B (es) 2025-03-20

Family

ID=51538486

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015011281A MX373965B (es) 2013-03-15 2014-03-17 Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae).
MX2020004724A MX389449B (es) 2013-03-15 2014-03-17 Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2021011946A MX2021011946A (es) 2013-03-15 2015-08-28 Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015011281A MX373965B (es) 2013-03-15 2014-03-17 Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021011946A MX2021011946A (es) 2013-03-15 2015-08-28 Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.

Country Status (30)

Country Link
US (9) US9616111B2 (es)
EP (3) EP3290046B1 (es)
JP (9) JP6184581B2 (es)
KR (4) KR20210021146A (es)
CN (2) CN105517559A (es)
AU (3) AU2014232912A1 (es)
BR (1) BR112015023207A8 (es)
CA (2) CA3054718A1 (es)
CY (2) CY1119419T1 (es)
DE (1) DE202014011208U1 (es)
DK (2) DK3290046T3 (es)
EA (1) EA201591278A1 (es)
ES (2) ES2713004T3 (es)
GB (1) GB2530921B (es)
HK (1) HK1250912B (es)
HR (2) HRP20171269T1 (es)
HU (2) HUE036224T2 (es)
IL (2) IL241549B (es)
LT (2) LT3290046T (es)
ME (2) ME03326B (es)
MX (3) MX373965B (es)
PL (2) PL2968434T3 (es)
PT (2) PT3290046T (es)
RS (2) RS56285B1 (es)
SG (2) SG10201707598QA (es)
SI (2) SI2968434T1 (es)
SM (2) SMT201700415T1 (es)
TR (1) TR201900319T4 (es)
WO (1) WO2014145519A2 (es)
ZA (3) ZA201507604B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700415T1 (it) 2013-03-15 2017-11-15 Shire Viropharma Inc Composizioni di c1-inh per l’uso nella prevenzione e nel trattamento dell’angioedema ereditario (hae)
CN105744949A (zh) * 2013-11-22 2016-07-06 夏尔维洛药品公司 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法
CA2977090A1 (en) * 2015-02-20 2016-08-25 Wolfram Schaefer Pharmaceutical formulations of c1 esterase inhibitor
HK1250623A1 (zh) * 2015-05-28 2019-01-11 Cornell University 腺相关病毒介导的c1ei递送作为用於血管性水肿的疗法
JP7189767B2 (ja) * 2015-11-19 2022-12-14 武田薬品工業株式会社 組換えヒトｃ１エステラーゼインヒビター及びその使用
EP3493832A1 (en) * 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
US20190183991A1 (en) * 2016-08-23 2019-06-20 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
CN110769848A (zh) * 2017-05-16 2020-02-07 瑞士奥克特珐玛公司 C1-酯酶抑制剂制剂
KR20210005549A (ko) 2018-02-28 2021-01-14 파밍 인텔렉츄얼 프라퍼티 비.브이. 전자간증의 치료 및 예방
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
AU2019288684A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Composition for eliciting infectious immunological tolerance
US12139537B2 (en) 2018-06-22 2024-11-12 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
AU2019288683A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
WO2021124793A1 (ja) * 2019-12-16 2021-06-24 ニプロ株式会社 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
US20240342258A1 (en) 2021-07-09 2024-10-17 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
AU678064B2 (en) 1993-09-01 1997-05-15 Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Method to reduce myocardial injury during acute myocardial infarction
JP2000507204A (ja) 1995-12-18 2000-06-13 ステイヒテイング・サンキン・ブロードボールジーニング Ｃ１―インヒビターの補体及び血液凝固阻害特性の強化
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
DE122011000002I1 (de) 2000-01-31 2011-05-05 Pharming Intellectual Pty Bv Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
AU2003300781A1 (en) 2002-09-25 2004-05-04 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
DK1626736T3 (da) 2003-05-16 2020-09-28 Pharming Intellectual Property B V C1-inhibitor med kort halveringstid til midlertidig behandling
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP1893227A2 (en) 2005-06-06 2008-03-05 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
CN101365478B (zh) * 2005-12-21 2016-06-22 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用
SI2380587T1 (en) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Use of a C1 inhibitor to prevent ischemic reperfusion injury
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
ES2753183T3 (es) 2007-02-12 2020-04-07 Csl Behring Gmbh Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ622583A (en) 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
AU2010306581B2 (en) 2009-10-16 2015-03-19 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
AU2011222883B2 (en) 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
ES2714999T3 (es) 2011-09-24 2019-05-31 Csl Behring Gmbh Terapia de combinación que usa inmunoglobulina e inhibidor de C1
US9452203B2 (en) 2011-12-22 2016-09-27 Csl Behring Gmbh Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
WO2013138730A1 (en) 2012-03-16 2013-09-19 Enzon Pharmaceuticals, Inc. Polymeric conjugates of c1-inhibitors
WO2014160499A2 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
SMT201700415T1 (it) * 2013-03-15 2017-11-15 Shire Viropharma Inc Composizioni di c1-inh per l’uso nella prevenzione e nel trattamento dell’angioedema ereditario (hae)
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック

Also Published As

Publication number Publication date
JP6877471B2 (ja) 2021-05-26
AU2014232912A1 (en) 2015-09-03
CY1119419T1 (el) 2018-03-07
AU2018229558A1 (en) 2018-10-04
MX2021011946A (es) 2021-11-17
SMT201700415T1 (it) 2017-11-15
JP2019073544A (ja) 2019-05-16
IL241549B (en) 2020-08-31
EP2968434B1 (en) 2017-06-28
NZ751555A (en) 2021-07-30
HUE036224T2 (hu) 2018-06-28
IL276153B (en) 2022-06-01
KR20210129267A (ko) 2021-10-27
EA201591278A1 (ru) 2016-03-31
AU2020203183B2 (en) 2022-06-02
IL276153A (en) 2020-09-30
AU2018229558B2 (en) 2020-03-05
US20200261556A1 (en) 2020-08-20
HRP20190270T1 (hr) 2019-04-05
HK1220403A1 (en) 2017-05-05
SI2968434T1 (sl) 2017-11-30
JP2021088599A (ja) 2021-06-10
JP2018119002A (ja) 2018-08-02
PL3290046T3 (pl) 2019-05-31
US10080788B2 (en) 2018-09-25
KR102430453B1 (ko) 2022-08-05
CA2904543A1 (en) 2014-09-18
CY1121653T1 (el) 2020-07-31
MX2020004724A (es) 2022-01-18
HUE041837T2 (hu) 2019-05-28
PT2968434T (pt) 2017-09-18
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
PL2968434T3 (pl) 2018-01-31
CN105517559A (zh) 2016-04-20
TR201900319T4 (tr) 2019-02-21
US11534482B2 (en) 2022-12-27
US20190160158A1 (en) 2019-05-30
JP6473535B2 (ja) 2019-02-20
JP2018119000A (ja) 2018-08-02
EP3290046A1 (en) 2018-03-07
JP6422520B2 (ja) 2018-11-14
EP3508213A1 (en) 2019-07-10
CN111529708A (zh) 2020-08-14
KR20150135242A (ko) 2015-12-02
US10105423B2 (en) 2018-10-23
BR112015023207A8 (pt) 2018-01-23
PT3290046T (pt) 2019-02-18
JP2019073546A (ja) 2019-05-16
MX2015011281A (es) 2016-03-03
SI3290046T1 (sl) 2019-04-30
JP2018119001A (ja) 2018-08-02
EP2968434A4 (en) 2016-03-02
ME03326B (me) 2019-10-20
EP2968434A2 (en) 2016-01-20
JP6473536B2 (ja) 2019-02-20
LT2968434T (lt) 2017-09-25
US9616111B2 (en) 2017-04-11
ES2639833T3 (es) 2017-10-30
ES2713004T3 (es) 2019-05-17
KR20220070049A (ko) 2022-05-27
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
US20180110844A1 (en) 2018-04-26
ME02865B (me) 2018-04-20
JP6877472B2 (ja) 2021-05-26
DK3290046T3 (en) 2019-03-18
SG11201507616VA (en) 2015-10-29
DK2968434T3 (en) 2017-09-11
SMT201900141T1 (it) 2019-05-10
US11364288B2 (en) 2022-06-21
WO2014145519A2 (en) 2014-09-18
JP2017105847A (ja) 2017-06-15
DE202014011208U1 (de) 2018-08-23
US20190160157A1 (en) 2019-05-30
JP6473534B2 (ja) 2019-02-20
JP6877470B2 (ja) 2021-05-26
ZA201507604B (en) 2018-05-30
CA3054718A1 (en) 2014-09-18
JP2019073545A (ja) 2019-05-16
HRP20171269T1 (hr) 2017-11-03
ZA201806793B (en) 2020-01-29
LT3290046T (lt) 2019-03-12
US20170224788A1 (en) 2017-08-10
AU2020203183A1 (en) 2020-06-04
US20180153972A1 (en) 2018-06-07
KR102579789B1 (ko) 2023-09-15
EP3290046B1 (en) 2019-01-02
WO2014145519A3 (en) 2014-12-31
HK1250912B (en) 2020-01-10
JP6184581B2 (ja) 2017-08-23
GB2530921A (en) 2016-04-06
KR20210021146A (ko) 2021-02-24
JP2016516073A (ja) 2016-06-02
BR112015023207A2 (pt) 2017-11-21
RS58351B1 (sr) 2019-03-29
SG10201707598QA (en) 2017-10-30
CA2904543C (en) 2019-10-08
GB2530921B (en) 2017-09-20
GB201519921D0 (en) 2015-12-23
MX373965B (es) 2020-07-13
ZA201706929B (en) 2019-05-29
US20180085441A1 (en) 2018-03-29
US20160015795A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
MX389449B (es) Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001368A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2017003142A1 (es) Composiciones que comprenden cepas bacterianas
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
UY37018A (es) Inhibidores bicíclicos de pad4
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2017006043A (es) Metodo y composiciones de anti-hcmv.
AR106769A1 (es) Composiciones que comprenden cepas bacterianas
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
BR112018007290A2 (pt) minha patente 1